Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis

References

• 1 Mclnnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205–2219 (2011).
  MedlineGoogle Scholar
• 2 Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int. J. Rheumatol. 2012, 946048 (2012).
  MedlineGoogle Scholar
• 3 Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin. Med. Insights Arthritis Musculoskelet. Disord. 5, 27–42 (2012).
  Medline CASGoogle Scholar
• 4 Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin. Immunol. 26(1), 88–96 (2014).
  Medline CASGoogle Scholar
• 5 Sato K, Tsuchiya M, Saldanha J et al. Reshaping a human antibody to inhibit the interleukin-6 dependent tumor cell growth. Cancer Res. 53(4), 851–856 (1993).
  Medline CASGoogle Scholar
• 6 Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73(3), 492–509 (2014).
  Medline CASGoogle Scholar
• 7 Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin. Exp. Immunol. 173(1), 8–17 (2013).
  Medline CASGoogle Scholar
• 8 Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur. J. Immunol. 40(7), 1830–1835 (2010).
  Medline CASGoogle Scholar
• 9 Tanaka T. Can IL-6 blockade rectify imbalance between Tregs and Th17 cells? Immunotherapy 5(7), 695–697 (2013).
  Medline CASGoogle Scholar
• 10 Fujimoto M, Serada S, Mihara M et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58(12), 3710–3719 (2008).
  Medline CASGoogle Scholar
• 11 Samson M, Audia S, Janikashvili N et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 64(8), 2499–2503 (2012).
  Medline CASGoogle Scholar
• 12 Niu Q, Cai B, Huang ZC, Shi YY, Wang LL. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol. Int. 32(9), 2731–2736 (2012).
  Medline CASGoogle Scholar
• 13 Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265(3), 621–636 (1990).
  Medline CASGoogle Scholar
• 14 Tanaka T, Ogata A, Kishimoto T. Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatol. Curr. Res. S4 (2013).http://omicsonline.org/targeting-of-interleukin-6-for-the-treatment-of-rheumatoid-arthritis-review-and-update-2161-1149.S4-002.php?aid=18750.
  Google Scholar
• 15 Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibrotic cells in the presence of soluble IL-6 receptor. Br. J. Rheumatol. 34(4), 321–325 (1995).
  Medline CASGoogle Scholar
• 16 Kotake S, Sato K, Kim KJ et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11(1), 88–95 (1996).
  Medline CASGoogle Scholar
• 17 Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology (Oxford) 47(11), 1635–1640 (2008).
  Medline CASGoogle Scholar
• 18 Nakahara H, Song J, Sugimoto M et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48(6), 1521–1529 (2003).
  Medline CASGoogle Scholar
• 19 Silacci P, Dayer JM, Desgeorges A et al. Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J. Biol. Chem. 273(22), 13625–13629 (1998).
  Medline CASGoogle Scholar
• 20 Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokine 51(2), 178–183 (2010).
  Medline CASGoogle Scholar
• 21 Hirano T, Matsuda T, Turne M et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18(11), 1797–1801 (1988).
  Medline CASGoogle Scholar
• 22 Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31(6), 784–788 (1988).
  Medline CASGoogle Scholar
• 23 Robak T, Gladalska A, Stepien H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 7(5), 347–353 (1998).
  Medline CASGoogle Scholar
• 24 Alonzi T, Fattori E, Lazzaro D et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187(4), 461–468 (1998).
  Medline CASGoogle Scholar
• 25 Takagi N, Mihara M, Moriya Y et al. Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41(12), 2117–2121 (1998).
  Medline CASGoogle Scholar
• 26 Sasai M, Saeki Y, Ohshima S et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42(8), 1635–1643 (1999).
  Medline CASGoogle Scholar
• 27 Kagari T, Doi H, Shimozato T. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169(3), 1459–1466 (2002).
  Medline CASGoogle Scholar
• 28 Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 11(8), 587–592 (1992).
  Medline CASGoogle Scholar
• 29 Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10(13), 4025–4031 (1991).
  Medline CASGoogle Scholar
• 30 Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J. Clin. Oncol. 3(9), 1202–1216 (1985).
  Medline CASGoogle Scholar
• 31 Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann. Rheum. Dis. 73(1), 95–100 (2014).
  Medline CASGoogle Scholar
• 32 Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine. 79(1), 85–87 (2012).
  MedlineGoogle Scholar
• 33 Ogata A, Kumanogoh A, Tanaka T. Pathological role of interleukin-6 in psoriatic arthritis. Arthritis 2012, 713618 (2012).
  MedlineGoogle Scholar
• 34 Maini RN, Taylor PC, Szechinski J et al. CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54(9), 2817–2829 (2006).
  Medline CASGoogle Scholar
• 35 Ogata A, Yoshida Y, Morishima A, Kumanogoh A, Tanaka T. IL-6 Targeting strategy for rheumatoid arthritis. In: Interleukin-6: Genetics, Clinical Applications and Role in Disease. D'Aquino J, DeVito EN (Eds). Nova Science Publishers, Inc, NY, USA, 111–150 (2013).
  Google Scholar
• 36 Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis. 66(9), 1162–1167 (2007).
  Medline CASGoogle Scholar
• 37 Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19(1), 12–19 (2009).
  Medline CASGoogle Scholar
• 38 Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69(1), 88–96 (2010).
  Medline CASGoogle Scholar
• 39 Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the TCZ in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58(10), 2968–2980 (2008).
  Medline CASGoogle Scholar
• 40 Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 371(9617), 987–997 (2008).
  Medline CASGoogle Scholar
• 41 Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomized placebo controlled trial. Ann. Rheum. Dis. 67(11), 1516–1523 (2008).
  Medline CASGoogle Scholar
• 42 Kremer JM, Blanco R, Brzosko M et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 63(3), 609–621 (2011).
  Medline CASGoogle Scholar
• 43 Witte T. Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint? Z. Rheumatol. 72(3), 279–286 (2013).
  Medline CASGoogle Scholar
• 44 Dougados M, Kissel K, Sheeran T et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis. 72(1), 43–50 (2013).
  Medline CASGoogle Scholar
• 45 Dougados M, Kissel K, Conaghan PG et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis. 73(5), 803–809 (2014).
  Medline CASGoogle Scholar
• 46 Takeuchi T, Kaneko Y, Atsumi T et al. Adding tocilizumab switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study). Ann. Rheum. Dis. 72(Suppl. 3), 62–63 (2013).
  Google Scholar
• 47 Takeuchi T, Kaneko Y, Atsumi T et al. Clinical and radiographic effects after 52-week of adding tocilizumab or switching to tocilizumab in RA patients with inadequate response to methotrexate: result from a prospective randomized controlled study (SURPRISE study). Ann. Rheum. Dis. 73(Suppl. 2), 686 (2014).
  Google Scholar
• 48 Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T. Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin. Rheumatol. 32(11), 1661–1666 (2013).
  MedlineGoogle Scholar
• 49 Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675–681 (2004).
  Medline CASGoogle Scholar
• 50 Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26–37 (2006).
  Medline CASGoogle Scholar
• 51 Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381(9877), 1541–1550 (2013).
  Medline CASGoogle Scholar
• 52 Hishitani Y, Ogata A, Shima Y et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand. J. Rheumatol. 42(4), 253–259 (2013).
  Medline CASGoogle Scholar
• 53 Nishimoto N, Amano K, Hirabayashi Y et al. Drug free remission/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study. Mod. Rheumatol. 24(1), 17–25 (2014).
  Medline CASGoogle Scholar
• 54 Aguilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J. Rheumatol. 40(7), 1069–1073 (2013).
  Medline CASGoogle Scholar
• 55 Dougados M, Donka T, Conaghan PG et al. Clinical and radiographic outcomes at two years and the effect of tocilizumab (TCZ) discontinuation following sustained remission in the second year of the ACT-RAY study. Ann. Rheum. Dis. 72(Suppl. 3), 63 (2013).
  Google Scholar
• 56 Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2, CD008794 (2011).
  Google Scholar
• 57 Fujiwara H, Nishimoto N, Hamano Y et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod. Rheumatol. 19(1), 64–68 (2009).
  MedlineGoogle Scholar
• 58 Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin. Biol. Ther. 11(4), 533–544 (2011).
  Medline CASGoogle Scholar
• 59 Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int. J. Rheum. Dis. doi:10.1111/1756-185X.12359 (2014) (Epub ahead of print).
  Google Scholar
• 60 Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 47(12), 1838–1840 (2008).
  Medline CASGoogle Scholar
• 61 Ogata A, Mori M, Hashimoto S et al. Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens. Mod. Rheumatol. 20(2), 130–133 (2010).
  Medline CASGoogle Scholar
• 62 Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. A systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 53(10), 1872–1885 (2014).
  Medline CASGoogle Scholar
• 63 Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin. Rheumatol. 30(11), 1471–1474 (2011).
  MedlineGoogle Scholar
• 64 Prins JR, Gomez-Lopez N, Robertson SA. Interleukin-6 in pregnancy and gestational disorders. J. Reprod. Immunol. 95(1–2), 1–14 (2012).
  Medline CASGoogle Scholar
• 65 Rubbert-Roth A, Goupille PM, Moosavi S, Hou A. First experiences with pregnancies in RA patients (pts) receiving tocilizumab (TCZ) therapy. Arthritis Rheum. 62(10 Suppl.), S161 (2010).
  Google Scholar
• 66 Nakamura I, Omata Y, Naito M, Ito K. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J. Rheumatol. 36(2), 459–460 (2009).
  MedlineGoogle Scholar
• 67 Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford) 53(7), 1321–1331 (2014).
  Medline CASGoogle Scholar
• 68 Strang AC, Bisoendial RJ, Kootte RS et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 229(1), 174–181 (2013).
  Medline CASGoogle Scholar
• 69 Rao VU, Pavlov A, Klearman M et al. Risk factors for major adverse cardiovascular (CV) events (MACE) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ). Ann. Rheum. Dis. 71(Suppl. 3), 356 (2012).
  Google Scholar
• 70 McInnes IB, Thompson L, Giles JT et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomized, placebo-controlled study. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2013-204345 (2013) (Epub ahead of print).
  Google Scholar
• 71 Sarwar N, Butterworth AS, Freitag DF et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379(9822), 1205–1213 (2012).
  MedlineGoogle Scholar
• 72 Ohta S, Tsuru T, Terao K et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J. Clin. Pharmacol. 54(1), 109–119 (2014).
  Medline CASGoogle Scholar
• 73 Ogata A, Tanimura K, Sugimoto T et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66(3), 344–354 (2014).
  Medline CASGoogle Scholar
• 74 Ogata A. Effectiveness and tolerability of subcutaneous tocilizumab in rheumatoid arthritis patients switched from intravenous tocilizumab: results from the extension period of the MUSASHI study. Arthritis Rheum. 64(Suppl. 10), S555 (2012).
  Google Scholar
• 75 Ogata A. Safety and efficacy of subcutaneous tocilizumab monotherapy in a long-term extension study in Japanese rheumatoid arthritis patients. Arthritis Rheum. 65(Suppl. 10), S605–S606 (2013).
  Google Scholar
• 76 Zhang X, Georgy A, Rowell L. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int. J. Clin. Pharmacol. Ther. 51(6), 443–455 (2013).
  Medline CASGoogle Scholar
• 77 Morcos PN, Zhang X, McIntyre C, Bittner B, Rowell L, Hussain Z. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int. J. Clin. Pharmacol. Ther. 51(7), 537–548 (2013).
  Medline CASGoogle Scholar
• 78 Zhang X, Chen YC, Fettner S et al. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 51(8), 620–630 (2013).
  Medline CASGoogle Scholar
• 79 Burmester GR, Rubbert-Roth A, Cantagrel AG et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann. Rheum. Dis. 73(1), 69–74 (2014).
  Medline CASGoogle Scholar
• 80 Burmester GR, Rubbert-Roth A, Cantagrel A et al. SUMMACTA: a randomized, double-blind parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional DMARDs in patients with moderate to severe RA. Ann. Rheum. Dis. 72(Suppl. 3), 615 (2013).
  Google Scholar
• 81 The efficacy and safety of tocilizumab subcutaneous versus tocilizumab intravenous, in combination with traditional DMARDs in patients with RA at 49 weeks (SUMMACTA). Burmester GR, Rubbert-Roth A, Cantagrel AG. Arthritis Rheum. 65(Suppl. 10), S203–S204 (2013).
  Google Scholar
• 82 Burmester G, Rubbert-Roth A, Cantagrel A et al. The efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann. Rheum. Dis. 73(Suppl. 2), 499–500 (2014).
  Google Scholar
• 83 Kivitz A, Olech E, Borofsky MA et al. Subcutaneous tocilizumab vs placebo in combination with disease modifying antirheumatic drugs in patients with Rheumatoid Arthritis. Arthritis Care Res. (Hoboken). 66(11), 1653–1661 (2014).
  Medline CASGoogle Scholar
• 84 Kivitz A, Olech E, Borofsky MA et al. The safety and efficacy of tocilizumab subcutaneous in combination with traditional DMARDs in patients with moderate to severe rheumatoid arthritis up to 48 weeks (BREVACTA). Arthritis Rheum. 65(Suppl. 10), S604–S605 (2013).
  Google Scholar
• 85 Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 53(2), 213–222 (2014).
  Medline CASGoogle Scholar